Description: BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Home Page: www.bi-nex.co.kr
7-48 SongDo-Dong
Incheon,
406-840
South Korea
Phone:
Officers
| Name | Title |
|---|---|
| Won-Seok Kim | Head of Production Division and Director |
| Young-Cheol Son | Head of Management Support Division and Director |
| Jung-Jin Lee | Head of Bio-Tech Research Center and Director |
| Byung-In Lee | Head of Bus. Operation Division and Director |
| Jung-Won Seo | Head of Bio Processing Division and Director |
| Myung-Cheol Lee | Managing Director |
| Soo-Yong Jin | Managing Director |
| Mr. Hyuk-Jong Lee | Managing Director |
| Doo-Hyun Kim | VP |
| Jung-Tak Moon | Chief Exec. Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 2.8183 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 503 |